Educational Stock Research Review: Akebia Ther (AKBA)
Welcome to this comprehensive educational research review of Akebia Ther (AKBA). This article is published by StockValueFinder.com to help investors understand how to apply quantitative screens to evaluate a company's financial health and valuation. By examining the specific metrics of Akebia Ther, we can learn how to distinguish between high-quality companies and those that present significant financial risks.
Akebia Ther operates within the Healthcare sector, specifically in the industry of Drug Manufacturers – Specialty & Generic. For those new to stock research, it is important to understand that specialty pharmaceutical companies often face unique challenges, including high research and development costs and regulatory hurdles. This review will break down the StockValueFinder metrics to show exactly where AKBA stands according to our quantitative standards.
Why the StockValueFinder Score Matters
The StockValueFinder score is a composite metric that aggregates various financial tests—including profitability, solvency, and valuation—into a single percentage. This score is designed to provide a quick snapshot of how many of our strict quality and value criteria a stock meets.
Akebia Ther (AKBA) currently holds a StockValueFinder score of 33%. In our system, a higher percentage indicates that a company has passed more of the fundamental tests. A score of 33% is relatively low, suggesting that the company failed the majority of the screens used to identify high-quality, value-oriented investments. Consequently, the current rating for AKBA is "AVOID."
For educational purposes, an investor should view a low score not as a definitive statement on the company's future, but as a signal that the current financial data does not align with a conservative, value-driven investment strategy. A stock that scores 80% or 90% would typically demonstrate strong earnings, low debt, and an attractive price, whereas a 33% score indicates significant gaps in those areas.
EPS Strength and Consistency
Earnings Per Share (EPS) is a critical metric because it tells us how much profit a company generates for each share of its stock. Consistency in EPS is vital; a company that grows its earnings steadily over several years is generally more predictable and less risky than one with volatile or negative earnings.
In the case of Akebia Ther, the EPS test result is "Did not pass." While specific historical EPS figures were not supplied for this report, the system recorded a failure. This means the company did not meet the minimum requirements for earnings growth or stability.
To understand this conceptually, imagine two companies. Company A has an EPS that has grown from $1.00 to $1.20 to $1.50 over three years. Company B has an EPS that fluctuates between -$0.50 and $0.10. Company A would pass the EPS strength test because it shows a clear trajectory of profitability. Company B would fail because its earnings are inconsistent or negative, making it difficult for investors to project future value. AKBA falls into the latter category according to the screen.
ROIC and Capital Efficiency
Return on Invested Capital (ROIC) is perhaps the most important metric for determining if a company is actually creating value. ROIC measures how efficiently a company uses its money (both debt and equity) to generate profit.
Akebia Ther has a reported ROIC of -2.15%.
From an educational standpoint, StockValueFinder generally prefers an ROIC of 10% or higher. A positive ROIC indicates that the company is earning more on its investments than it costs to get that capital. A negative ROIC, such as -2.15%, indicates that the company is currently losing money on the capital it has deployed into the business.
For example, if a company invests $100 million into a new factory and generates $15 million in annual profit, its ROIC is 15%. This is a strong result. If another company invests $100 million and only generates $4 million in profit, its ROIC is 4%. While 4% is positive, it is much weaker than 15%. When the ROIC is negative, as it is with AKBA, the company is effectively eroding its capital base rather than growing it.
Interest Coverage and Financial Safety
Interest coverage is a solvency ratio that describes how easily a company can pay the interest expenses on its outstanding debt. It is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expenses.
The interest coverage test for Akebia Ther resulted in "Did not pass." StockValueFinder prefers an interest coverage ratio of 6 or higher. This provides a "margin of safety," ensuring that even if earnings dip, the company can still service its debt without risking bankruptcy.
To illustrate, consider a company that earns $60,000 a year and owes $10,000 in annual interest; its coverage is 6x. This is considered healthy. Now consider a company that earns $20,000 and owes $10,000 in interest; its coverage is only 2x. If that company's earnings drop by just 20%, it will struggle to pay its lenders. Because AKBA failed this test, it suggests the company lacks a sufficient cushion to cover its interest obligations comfortably.
Debt Payback and Balance Sheet Discipline
Debt payback is a metric that estimates how many years it would take for a company to pay off its total debt using its current annual earnings. This is a measure of balance sheet discipline.
Akebia Ther passed this test, with a debt payback period of 0.71 years.
StockValueFinder considers a debt payback period of 3 years or less to be attractive. A shorter payback period means the company is not overly burdened by long-term debt relative to its current financial capacity to clear those obligations.
For example, a company that can pay off all its debt in 1.5 years is in a much stronger position than a company that would take 7 years to do so. A 7-year payback period leaves the company vulnerable to interest rate hikes or economic downturns. With a value of 0.71 years, AKBA demonstrates a strong ability to handle its total debt load quickly, which is one of the few areas where the company passed the screen.
P/E Ratio and Valuation Discipline
The Price-to-Earnings (P/E) ratio is the most common tool for determining if a stock is overvalued or undervalued. It compares the current share price to the company's earnings per share.
Akebia Ther has a P/E ratio of -432.46.
In a standard value-investing framework, StockValueFinder prefers a P/E ratio of 15 or lower. A low P/E suggests you are paying less for every dollar of profit the company makes. For example, a P/E of 8 is generally more value-oriented than a P/E of 40, provided the business quality is sound.
However, AKBA's P/E is negative. A negative P/E occurs when a company has negative earnings (losses). While the system marked the P/E valuation test as "Passed," this is a technical result often seen in screens when a stock's price has dropped so significantly that it no longer carries a traditional "growth" premium, or because the earnings are so deeply negative that the ratio becomes mathematically distorted. In practical terms, a negative P/E means the company is not currently profitable, which is a significant risk factor.
Moving Average Trend and Entry Timing
While fundamental metrics tell us *what* to buy, technical trends help us decide *when* to buy. We use moving averages to determine if a stock is in an uptrend or a downtrend.
The moving average signal for AKBA is "SELL / AVOID TREND." Additionally, the entry signal is listed as "N/A."
It is important to understand that a trend signal is used for timing discipline. It is not a guarantee that a stock must rise or fall, but rather a reflection of current market sentiment. When a stock is in a "Sell/Avoid" trend, it means the price is generally trading below its average price over a set period, indicating a lack of buyer momentum.
For this ticker, there is no Limit Buy Idea, no Pullback Zone, and no Risk Stop / Trend Risk Level provided (all marked N/A). These are educational reference levels used to manage risk; their absence here indicates that the stock does not currently meet the technical criteria for a disciplined entry point.
Overall Financial Strengths and Weaknesses
When we aggregate these numbers, a clear picture of Akebia Ther's current financial state emerges.
**Strengths:** The primary strength of AKBA is its debt payback period. At 0.71 years, the company is not burdened by a mountain of debt that it cannot manage. This passed the StockValueFinder screen and suggests that the balance sheet is not the primary source of risk.
**Weaknesses:** The weaknesses are centered on profitability and efficiency. The ROIC of -2.15% shows that the company is not generating a positive return on its invested capital. The failure of the EPS strength test and the interest coverage test further highlight a lack of consistent profitability and a thin margin of safety regarding interest payments. Finally, the negative P/E ratio confirms that the company is operating at a loss.
Risks and Limitations
Investing in specialty drug manufacturers involves significant risks. The failure of the ROIC and EPS tests suggests that AKBA is currently in a phase where it is spending more than it is earning. For any company, a negative ROIC is a warning sign that the business model is not yet producing a surplus.
Furthermore, the "SELL / AVOID TREND" signal indicates that the market is currently pricing the stock downward. With a recent price of $0.56, the stock is trading at a very low nominal value, which often accompanies high volatility and higher risk of capital loss.
Educational Conclusion
Evaluating Akebia Ther (AKBA) provides a textbook example of why it is important to look at multiple metrics rather than just one. If an investor looked only at the debt payback period (0.71 years), they might think the company is in great shape. However, when that is paired with a negative ROIC (-2.15%), a failed interest coverage test, and a negative P/E ratio, the full picture becomes clear: the company has a manageable debt load but is struggling to generate profit.
With a StockValueFinder score of 33% and an "AVOID" rating, AKBA does not meet the criteria for a high-quality value investment. For those learning to screen stocks, the lesson here is to seek companies that pass across all categories—earnings, efficiency, safety, and valuation—rather than those that pass only one or two.
This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.
Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings
Specializing in global financial markets, macroeconomic trends, and equity valuation, Omar Gemani brings a disciplined, research-driven perspective to investment analysis. His editorial approach emphasizes company fundamentals, earnings sustainability, financial strength, and long-term growth potential. Combining fundamental analysis with broader economic indicators, Omar evaluates investment opportunities while highlighting market uncertainty, valuation risks, and the importance of capital preservation.